PUBLISHER: IMARC | PRODUCT CODE: 1540817
PUBLISHER: IMARC | PRODUCT CODE: 1540817
The global genotyping market size reached US$ 19.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 57.4 Billion by 2032, exhibiting a growth rate (CAGR) of 12.5% during 2024-2032.
Genotyping refers to an analytical procedure that examines DNA sequences to determine the genetic constitution in the genotypes of living organisms, including humans, plants, animals, and microorganisms. Genetic tests enable scientists to examine a variety of genetic deviations, such as changes in DNA structure and single nucleotide polymorphisms, by detecting genetic differences through biological assays. By using this information, the differences between individuals can be compared while providing data related to the genetic history of an individual. Genotyping of microorganisms, such as viruses and bacteria, on the other hand, helps prevent the spread of pathogens by pinpointing the source of viral and bacterial diseases.
The global market is majorly driven by the rising demand for genotypic-based diagnostic testing in healthcare facilities across the globe. This can be attributed to the increasing prevalence of chronic diseases, including cancer and genetic disorders. In addition to this, the rising adoption of bioinformatics solutions in data analysis and pharmacogenomics in the drug discovery and development processes is also providing an impetus to the market growth. The market is further driven by the substantial rise in investments in research and development (R&D) activities focusing on genomic drug development and precision medicine research. Apart from this, the escalating demand for reagents for the augmenting volumes of genotyping tests on the global level is creating a positive outlook for the market. Some of the other factors that are contributing to the growth of the market include the rising geriatric population that is susceptible to developing numerous medical conditions, continual technological advancements in genotyping products, the growing awareness regarding personalized medicines among the masses and a considerable expansion of healthcare expenditure.
IMARC Group provides an analysis of the key trends in each sub-segment of the global genotyping market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product and service, technology, application and end user.
Instruments
Reagents and Kits
Software and Services
Polymerase Chain Reaction (PCR)
Capillary Electrophoresis
Microarray
Sequencing
Mass Spectrometry
Others
Pharmacogenomics
Diagnostics and Personalized Medicine
Agricultural Biotechnology
Animal Genetics
Others
Pharmaceutical and Biopharmaceutical Companies
Diagnostics and Research Laboratories
Academic Institutes
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Bio-Rad Laboratories Inc., Danaher Corporation, Eurofins Scientific SE, F. Hoffmann-La Roche AG, Illumina Inc., Laboratory Corporation of America Holdings, Qiagen N.V, Standard BioTools Inc. and Thermo Fisher Scientific Inc.